TY - JOUR T1 - Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma JO - Medicina Clínica (English Edition) T2 - AU - Díez,Juan J. AU - Grande,Enrique AU - Iglesias,Pedro SN - 23870206 M3 - 10.1016/j.medcle.2014.01.002 DO - 10.1016/j.medcle.2014.01.002 UR - https://www.elsevier.es/en-revista-medicina-clinica-english-edition--462-articulo-postoperative-radioiodine-ablation-in-patients-S2387020615000121 AB - Most patients with newly diagnosed differentiated thyroid carcinoma have tumours with low risk of mortality and recurrence. Standard therapy has been total or near total thyroidectomy followed by postoperative radioiodine remnant ablation (RRA). Although RRA provides benefits, current clinical guidelines do not recommend it universally, since an increase in disease-free survival or a decrease in mortality in low risk patients has not been demonstrated so far. Advancements in our understanding of the biological behaviour of thyroid cancer have been translated into the clinic in a personalised approach to the patients based on their individual risk of recurrence and mortality. Current evidence suggests that RRA is not indicated in most low-risk patients, especially those with papillary carcinomas smaller than 1cm, without extrathyroidal extension, unfavourable histology, lymph node involvement or distant metastases. Follow-up of these patients with serial measurements of serum thyroglobulin and neck ultrasound is adequate. Careful evaluation of all risk factors of clinical relevance will allow a more realistic assessment of each individual patient. ER -